| Timetable |
| Download Conference Program |
| Download All Abstracts |
| Zoom Access |
| Corporate Program |
Poster Presentations
Day 2, June 23（Mon.）
Room P (Maesato East, Foyer, Ocean Wing)
- 2P-PM-01
Phosphoproteomics Identifies CDK18 as a Key Driver in ccRCC Progression and Potential Therapeutic Target
(1Fu Jen Univ., 2Department of Medical Research, Cathay General Hospital, 3National Defense Medical Center, 4Sijhih Cathay General Hospital, 5Cathay General Hospital)
oWei-Chi Ku1, Chi-Jung Huang2,3, Shao-Kuan Chen4, Yen-Chieh Wang1,5
Background: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma, with high mortality in metastatic stages. This study aims to identify therapeutic targets to improve ccRCC prognosis and treatment.
Objective: To perform comprehensive phosphoproteomic profiling of RCC clinical subtypes and investigate the role of CDK18 in ccRCC progression.
Methods: We analyzed 26 clinical RCC tumor samples using quantitative phosphoproteomics. Western blotting and immunohistochemical staining validated the findings. CDK18-interacting proteins were identified through affinity purification-mass spectrometry (AP-MS).
Results: Phosphoproteomic analysis revealed distinct phosphorylation patterns across RCC subtypes. CDK18 was differentially upregulated in ccRCC, with expression and phosphorylation levels increasing with clinical stages. CDK18 knockdown in 786-O ccRCC cells reduced cellular growth and increased focal adhesion kinase (FAK) phosphorylation, indicating roles in cell proliferation, adhesion, and migration. AP-MS identified potential CDK18-interacting proteins, including one MAP kinase. Co-immunoprecipitation and western blotting validated the interaction between CDK18 and the MAP kinase.
Conclusion: CDK18 is a crucial player in ccRCC carcinogenesis, influencing cell proliferation, adhesion, and migration. Identifying CDK18-interacting proteins supports its potential as a therapeutic target. Future studies will focus on elucidating the CDK18 signaling axis to develop targeted therapies for ccRCC.